XBiotech Inc.

Equities

XBIT

CA98400H1029

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 01/06/2024 am IST			5-day change	1st Jan Change
7.25 ^USD	-3.20%		-12.76%	+81.25%

15/03	XBiotech Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
04/01	XBiotech Inc. to Begin Constructing New R&D Facility on Its 48-Acre Campus	CI

XBiotech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022

May 11, 2022 at 01:24 am IST

XBiotech Inc. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported revenue was USD 0.5 million compared to USD 4.85 million a year ago. Net loss was USD 5.4 million compared to USD 2.57 million a year ago. Basic loss per share from continuing operations was USD 0.18 compared to USD 0.09 a year ago.

Latest news about XBiotech Inc.

XBiotech Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	16/03	CI
XBiotech Inc. to Begin Constructing New R&D Facility on Its 48-Acre Campus	04/01	CI
XBiotech Inc. announced that it expects to receive $10 million in funding	03/01	CI
Xbiotech Appoints Alan Kivitz M.D. Lead Investigator & Study Chairman for Its Clinical Research Program for Natrunix in Rheumatoid Arthritis	14/11	CI
XBiotech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11	CI
Xbiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, A Novel Candidate Therapy for Stroke	26/23/26	CI
XBiotech Inc.(NasdaqGS:XBIT) dropped from S&P Global BMI Index	18/23/18	CI
Xbiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic Cancer	30/23/30	CI
XBiotech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/23/11	CI
Tranche Update on XBiotech Inc.'s Equity Buyback Plan announced on May 17, 2023.	20/23/20	CI
XBiotech Inc.'s Equity Buyback announced on May 17, 2023, has expired with 3,561 shares, representing 0.01% for $0.01 million.	15/23/15	CI
XBiotech Gets FDA Approval for Phase 2 Study of Potential Treatment for Rheumatoid Arthritis	22/23/22	MT
XBiotech Inc. announces an Equity Buyback for $80 million worth of its shares.	17/23/17	CI
XBiotech Inc. authorizes a Buyback Plan.	17/23/17	CI
XBiotech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	11/23/11	CI
XBiotech Enrolls First Subject in Phase 1 Trial of Stroke Therapy Hutrukin; Shares Rise	17/23/17	MT
XBiotech Inc. Announces Executive Changes	15/23/15	CI
XBiotech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	10/22/10	CI
XBiotech Study of Natrunix Therapy to Treat Colorectal Cancer Enrolls First Patient	13/22/13	MT
XBiotech Inc. Announces First Patient Enrolled into the French National Cancer Institute Sponsored Phase I/Ii/Iii Clinical Study for Natrunix™ Therapy for Colorectal Cancer	13/22/13	CI
XBiotech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	10/22/10	CI
XBiotech Inc.(NasdaqGS:XBIT) dropped from Russell 2500 Index	24/22/24	CI
XBiotech Inc.(NasdaqGS:XBIT) dropped from Russell Small Cap Comp Value Index	24/22/24	CI
XBiotech Inc.(NasdaqGS:XBIT) dropped from Russell 2500 Value Index	24/22/24	CI
XBiotech Inc.(NasdaqGS:XBIT) dropped from Russell Small Cap Completeness Index	24/22/24	CI

Chart XBiotech Inc.

Duration

Period

More charts

Company Profile

XBiotech Inc. is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies for treating a variety of diseases, such as inflammatory conditions like rheumatology, infectious disease, cardiovascular disease and cancer. The Company's True Human monoclonal antibodies are derived from human donors that mount a natural human immune response. The Company is focused on therapies that block a potent substance, known as interleukin-1 alpha (IL-1a), that mediates a number of pathophysiological processes including tissue breakdown (i.e. synovium, cartilage, bone), paraneoplastic angiogenesis and tumor stroma remodeling, formation of blood clots, malaise, muscle wasting and general inflammation. It has various candidate products including Natrunix. It has a clinical-stage therapeutic for methicillin resistant Staphylococcus aureus (MRSA), and several pre-clinical-stage therapeutics, including an oral delivery antibody therapeutic for colon infection by C. difficile.

Sector

Biotechnology & Medical Research

Calendar

20/06/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
XBIOTECH INC.	+81.25%	22Cr
VERTEX PHARMACEUTICALS INCORPORATED	+11.91%	12TCr
REGENERON PHARMACEUTICALS, INC.	+11.60%	11TCr
BIONTECH SE	-4.68%	2.43TCr
ARGENX SE	-0.82%	2.2TCr
GENMAB A/S	-10.12%	1.82TCr
WUXI APPTEC CO., LTD.	-42.12%	1.64TCr
BEIGENE, LTD.	-17.47%	1.56TCr
NEUROCRINE BIOSCIENCES, INC.	+2.77%	1.36TCr
SAREPTA THERAPEUTICS, INC.	+34.58%	1.23TCr

Bio Therapeutic Drugs